Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Urology Année : 2023

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Silke Gillessen (1, 2) , Alberto Bossi (3) , Ian D Davis (4) , Johann de Bono (5, 6) , Karim Fizazi (3, 7) , Nicholas D James (5) , Nicolas Mottet (8, 9) , Neal Shore (10) , Eric Small (11) , Matthew Smith (12) , Christopher Sweeney (13, 14, 15) , Bertrand Tombal (16) , Emmanuel S Antonarakis (17, 18) , Ana M Aparicio (19) , Andrew J Armstrong (20) , Gerhardt Attard (21) , Tomasz M Beer (22, 23) , Himisha Beltran (13, 14, 15) , Anders Bjartell (24) , Pierre Blanchard (25, 26, 27) , Alberto Briganti (28) , Rob G Bristow (29, 30) , Muhammad Bulbul (31) , Orazio Caffo (32) , Daniel Castellano (33) , Elena Castro (34) , Heather H Cheng (35) , Kim N Chi (36, 37) , Simon Chowdhury (38) , Caroline S Clarke (39) , Noel Clarke (40, 30) , Gedske Daugaard (41) , Maria de Santis (42, 43) , Ignacio Duran (44) , Ros Eeles (6, 5) , Eleni Efstathiou (45) , Jason Efstathiou (12) , Onyeanunam Ngozi Ekeke (46) , Christopher P Evans (47) , Stefano Fanti (48) , Felix Y Feng (49) , Valerie Fonteyne (50) , Nicola Fossati (2) , Mark Frydenberg (51, 4) , Daniel George (20, 52) , Martin Gleave (37) , Gwenaelle Gravis (53, 54) , Susan Halabi (52) , Daniel Heinrich (55) , Ken Herrmann (56, 57, 58) , Celestia Higano (37) , Michael S Hofman (59, 60) , Lisa G Horvath (61, 62) , Maha Hussain (63, 64) , Barbara Alicja Jereczek-Fossa (65, 66) , Robert Jones (67) , Ravindran Kanesvaran (68) , Pirkko-Liisa Kellokumpu-Lehtinen (69, 70) , Raja B Khauli (71, 31) , Laurence Klotz (72, 73) , Gero Kramer (43) , Raya Leibowitz (74) , Christopher J Logothetis (19, 75) , Brandon A Mahal (76, 77) , Fernando Maluf (78) , Joaquin Mateo (79, 80) , David Matheson (81) , Niven Mehra (82) , Axel Merseburger (83) , Alicia K Morgans (14, 15, 13) , Michael J Morris (84) , Hind Mrabti (85) , Deborah Mukherji (86, 31) , Declan G Murphy (87, 60) , Vedang Murthy (88) , Paul L Nguyen (13, 15, 14) , William K Oh (89, 90) , Piet Ost (50) , Joe M O'Sullivan (5, 91) , Anwar R Padhani (92, 5) , Carmel Pezaro (93) , Darren M C Poon (94, 95) , Colin C Pritchard (35) , Danny M Rabah (96, 97) , Dana Rathkopf (84) , Robert E Reiter (98) , Mark A Rubin (99) , Charles J Ryan (100) , Fred Saad (101) , Juan Pablo Sade (102) , Oliver A Sartor (103) , Howard I Scher (84, 104) , Nima Sharifi (105) , Iwona Skoneczna (106, 107) , Howard Soule (108) , Daniel E Spratt (109) , Sandy Srinivas (110) , Cora N Sternberg (111, 112, 113, 114) , Thomas Steuber (115) , Hiroyoshi Suzuki (116) , Matthew R Sydes (39) , Mary-Ellen Taplin (15, 13, 14) , Derya Tilki (115, 117) , Levent Türkeri (118) , Fabio Turco (1) , Hiroji Uemura (119) , Hirotsugu Uemura (120) , Yüksel Ürün (121) , Claire L Vale (39) , Inge van Oort (82) , Neha Vapiwala (122) , Jochen Walz (53) , Kosj Yamoah (123, 124) , Dingwei Ye (125, 126) , Evan Y Yu (127, 128) , Almudena Zapatero (129, 130) , Thomas Zilli (1, 131) , Aurelius Omlin (132)
1 IOSI - Oncology Institute of Southern Switzerland
2 USI - Università della Svizzera italiana = University of Italian Switzerland
3 IGR - Institut Gustave Roussy
4 Faculty of Medicine, Nursing and Health Sciences - Monash university [Victoria]
5 The institute of cancer research [London]
6 The Royal Marsden NHS Foundation Trust [London]
7 Université Paris-Saclay
8 Service de Gynécologie Obstétrique [CHRU Besançon]
9 UJM - Université Jean Monnet - Saint-Étienne
10 CURC - Carolina Urologic Research Center [Myrtle Beach, USA]
11 UC San Francisco - University of California [San Francisco]
12 Massachusetts General Hospital [Boston]
13 Dana-Farber Cancer Institute [Boston]
14 Brigham and Women's Hospital [Boston]
15 HMS - Harvard Medical School [Boston]
16 Cliniques Universitaires Saint-Luc [Bruxelles]
17 University of Minnesota Medical School
18 Masonic Cancer Center
19 The University of Texas M.D. Anderson Cancer Center [Houston]
20 Duke Cancer Institute Durham, North Carolina, USA.
21 UCLH - University College London Hospitals
22 Knight Cancer Institute
23 UP - University of Portland
24 Skane University Hospital [Lund]
25 CESP - Centre de recherche en épidémiologie et santé des populations
26 U1018 (Équipe 2) - Oncostat
27 Département de radiothérapie [Gustave Roussy]
28 San Raffaele Scientific Institute
29 University of Manchester [Manchester]
30 The Christie NHS Foundation Trust [Manchester, Royaume-Uni]
31 AUB - American University of Beirut Faculty of Medicine and Medical Center
32 Medical Oncology, Santa Chiara Hospital, Trento, Italy
33 Hospital Universitario 12 de Octubre [Madrid]
34 IBIMA Plataforma BIONAND - Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina = Biomedical Research Institute of Málaga and Nanomedicine Platform
35 University of Washington [Seattle]
36 VPC - Vancouver Prostate Centre [Vancouver General Hospital]
37 University of British Columbia [Vancouver]
38 Guy's and St Thomas' NHS Foundation Trust
39 UCL - University College of London [London]
40 Salford Royal NHS Foundation Trust [Salford, UK]
41 Copenhagen University Hospital
42 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
43 Medizinische Universität Wien = Medical University of Vienna
44 Hospital Universitario Marqués de Valdecilla [Santander]
45 The Houston Methodist Research Institute
46 University of Port Harcourt
47 UC Davis - University of California [Davis]
48 AOUB - IRCCS Azienda Ospedaliero-Universitaria di Bologna
49 UC - University of California
50 Ghent University Hospital
51 Monash University [Melbourne]
52 Duke University [Durham]
53 IPC - Institut Paoli-Calmettes
54 AMU SMPM MED - Aix-Marseille Université - École de médecine
55 IHT - Innlandet Hospital Trust [Gjøvik, Norway]
56 Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
57 DKTK - German Cancer Consortium [Heidelberg]
58 AöR - University Hospital Essen
59 Peter MacCallum Cancer Centre
60 University of Melbourne
61 Garvan Institute of medical research
62 The University of Sydney
63 Northwestern University [Evanston]
64 Robert H. Lurie Comprehensive Cancer Center
65 UNIMI - Università degli Studi di Milano = University of Milan
66 EIO - European Institute of Oncology IRCCS [Milan, Italy]
67 University of Glasgow
68 NCCS - National Cancer Centre Singapore
69 Tampere University Hospital
70 University of Tampere [Finland]
71 Naef K. Basile Cancer Institute (NKBCI), Breast Center of Excellence
72 Sunnybrook - Sunnybrook Health Sciences Centre [Toronto]
73 University of Toronto
74 TAU - Tel Aviv University
75 University of Athens Medical School [Athens]
76 University of Miami
77 S3C - Sylvester Comprehensive Cancer Center [Miami, FL, USA]
78 Hospital Israelita Albert Einstein [São Paulo, Brazil]
79 Vall d'Hebron University Hospital [Barcelona]
80 Vall d'Hebron Institute of Oncology (VHIO)
81 University of Wolverhampton
82 Radboud University Medical Center [Nijmegen]
83 University Hospital Schleswig-Holstein [Kiel, Germany]
84 Memorial Sloane Kettering Cancer Center [New York]
85 LERMA, Mohammadia School of Engineering, University Mohamed V, Rabat, Morocco
86 CMC - Clemenceau Medical Center
87 Peter MacCallum Cancer Centre [Melbourne, Australie]
88 Tata Memorial Centre
89 MSSM - Icahn School of Medicine at Mount Sinai [New York]
90 The Tisch Cancer Institute
91 Belfast City Hospital
92 MV2C - Mount Vernon Cancer Centre [Northwood, UK]
93 Sheffield Teaching Hospitals NHS Foundation Trust [Sheffield, Royaume-Uni]
94 HKSH - Hong Kong Sanatorium and Hospital [Hong Kong]
95 CUHK - The Chinese University of Hong Kong [Hong Kong]
96 KSU - King Saud University [Riyadh]
97 KFSHRC - King Faisal Specialist Hospital and Resarch Centre [Riyadh, Saudi Arabia]
98 UCLA - University of California [Los Angeles]
99 UNIBE - Universität Bern / University of Bern
100 UMC - University of Minnesota [Crookston]
101 CHUM - Centre Hospitalier de l'Université de Montréal
102 IAF - Instituto Alexander Fleming [Buenos Aires, Argentina]
103 Tulane University
104 Weill Medical College of Cornell University [New York]
105 Cleveland Clinic
106 Rafal Masztak Grochowski Hospital [Warsaw, Poland]
107 Maria Sklodowska-Curie National Research Institute of Oncology [Krakow, Poland]
108 PCF - Prostate Cancer Foundation [Santa Monica, CA, USA]
109 UH SCC - University Hospitals Seidman Cancer Center [Cleveland, OH, USA]
110 Stanford University Medical Center
111 Sandra and Edward Meyer Cancer Center [New-York]
112 New York Presbyterian Hospital
113 Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA
114 Weill Cornell Medicine [Cornell University]
115 University Hospital Hamburg-Eppendorf
116 Toho University
117 Kocaeli University Hospital
118 Acibadem Mehmet Ali Aydınlar University
119 YCU - Yokohama City University
120 Kindai University
121 Ankara University School of Medicine [Turkey]
122 University of Pennsylvania
123 H. Lee Moffitt Cancer Center and Research Institute
124 USF - University of South Florida [Tampa]
125 Fudan University Shanghai Cancer Center [China]
126 Shanghai Medical College, Fundan University [Shanghai China]
127 University of Washington [Tacoma]
128 FHCRC - Fred Hutchinson Cancer Research Center [Seattle]
129 Hospital Universitario de La Princesa
130 Health Research Institute [Madrid, Espagne]
131 UNIGE - Université de Genève = University of Geneva
132 UZH - Universität Zürich [Zürich] = University of Zurich
Nima Sharifi
  • Fonction : Auteur
Hiroyoshi Suzuki
  • Fonction : Auteur

Résumé

Background: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.
Fichier principal
Vignette du fichier
2023_Blanchard_EurUrol.pdf (762.02 Ko) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

inserm-04494406 , version 1 (07-03-2024)

Identifiants

Citer

Silke Gillessen, Alberto Bossi, Ian D Davis, Johann de Bono, Karim Fizazi, et al.. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 2023, 83 (3), pp.267 - 293. ⟨10.1016/j.eururo.2022.11.002⟩. ⟨inserm-04494406⟩
5 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More